A trial in progress will evaluate the combination of immunotherapy with tadalafil and vancomycin.
SBRT preserved quality of life and eliminated need for post-TACE hospitalization in patients with hepatocellular carcinoma.
The phase 1b included 104 patients who received lenvatinib 12 mg per day or 8 mg per day plus pembrolizumab 200 mg on day 1 of a 21-day cycle.
The administration of apatinib in patients with advanced HCC led to improvements in survival with a manageable safety profile.
Noninvasive method could help monitor treatment responses.
Early results warrant further exploration of intrahepatic injection of T-VEC, a genetically modified oncolytic HSV-1, in combination with pembrolizumab.